前列腺影像质量(PI-QUAL):PRECISION试验中的mpMRI质控评分系统
PRECISION试验是多中心随机研究,证实mpMRI靶向活检优于标准经直肠超声引导活检。本研究提出PI-QUAL评分(1-5分)评估mpMRI质量,从22个中心随机抽取58/252(23%)例扫描由两名放射科医生共识评估。结果显示95%扫描PI-QUAL≥3,60%≥4;T2WI诊断质量95%,DWI 79%,DCE 66%。
要点
- PI-QUAL评分1-5分,评估mpMRI各序列诊断质量。
- PRECISION试验中95%扫描PI-QUAL≥3,60%≥4。
- T2WI诊断质量最高(95%),DCE最低(66%)。
核心结论
- PI-QUAL是首个用于评估前列腺mpMRI诊断质量的Likert 1-5分评分系统。
- PRECISION试验中mpMRI整体质量良好,95%扫描PI-QUAL≥3。
研究设计与样本
- 从PRECISION试验22个中心随机抽取58/252(23%)例mpMRI扫描。
- 由两名经验丰富的放射科医生共识评估,对病理结果设盲。
主要发现
- 55例(95%)扫描PI-QUAL≥3,达到足够诊断质量。
- 35例(60%)扫描PI-QUAL≥4,达到良好或最佳诊断质量。
- 各序列诊断质量:T2WI 55/58(95%),DWI 46/58(79%),DCE 38/58(66%)。
关键数值与推荐
- PI-QUAL 1分:无mpMRI序列达到诊断质量;5分:每个序列独立达到最佳诊断质量。
- PI-QUAL≥3定义为足够诊断质量,≥4定义为良好或最佳诊断质量。
临床怎么用
- 可用于评估和比较不同中心mpMRI扫描质量,促进质量改进。
- DCE序列质量有提升空间,需关注对比剂使用图像质量。
局限性
- 仅评估58例扫描,样本量有限。
- 需进一步验证该评分系统。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The PRECISION trial was a multicentre randomised study that demonstrated that multiparametric magnetic resonance imaging (mpMRI)-targeted biopsy is superior to standard transrectal ultrasound-guided biopsy for the detection of prostate cancer. The outcomes of studies reporting mpMRI-targeted biopsies are dependent on the quality of the mpMRI but there are currently no scoring systems available for evaluating this. We introduced a novel scoring system, the Prostate Imaging Quality (PI-QUAL) score, to assess the quality of scans in the PRECISION trial. PI-QUAL is a score on a Likert scale from 1 to 5, where 1 means that no mpMRI sequences are of diagnostic quality and 5 implies that each sequence is independently of optimal diagnostic quality. Fifty-eight out of 252 (23%) mpMRI scans chosen at random from each of the 22 centres in this trial were evaluated by two experienced radiologists from the coordinating trial centre, in consensus, blinded to pathology results. Overall, the mpMRI quality in the centres participating in PRECISION was good. MpMRI quality was of sufficient diagnostic quality (PI-QUAL ≥3) for 55 scans (95%) and of good or optimal diagnostic quality (PI-QUAL ≥4) for 35 scans (60%). Fifty-five out of 58 (95%) scans were of diagnostic quality for T2WI, followed by DWI (46/58 scans; 79%), and DCE (38/58 scans; 66%). Further validation of this scoring system is warranted. PATIENT SUMMARY: In this study we developed a scoring system (PI-QUAL) to assess the quality of multiparametric magnetic resonance imaging (mpMRI) in prostate cancer detection. We used scans from 22 centres that participated in the PRECISION trial. Although there was room for improvement in images that used intravenous contrast, we found that mpMRI in the PRECISION trial was of sufficient diagnostic quality (PI-QUAL score ≥3) for 95% of the scans.
引用
- Giganti F, Allen C, Emberton M, et al. Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the Prostate from the PRECISION trial. Eur Urol Oncol. 2020. PMID: 32646850. doi:10.1016/j.euo.2020.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。